Arming cells. Against cancer. For good.
Founded in 2008, Adaptimmune develops novel T-cell receptor (TCR-T) immunotherapies for cancer treatment. The company pioneered the first FDA-approved engineered cell therapy for solid tumors (TECELRA). Headquartered in Philadelphia with UK operations, it employs approximately 300-400 people across its integrated cell therapy platform.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account